Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma
Pediatric Blood & Cancer2005Vol. 48(2), pp. 132–139
Citations Over TimeTop 10% of 2005 papers
Lars M. Wagner, Nancy McAllister, Robert E. Goldsby, Aaron R. Rausen, Rene McNall‐Knapp, M. Beth McCarville, Karen Albritton
Abstract
Temozolomide and protracted intravenous irinotecan given in 21-day courses was tolerable and active in patients with advanced ES. Home administration of irinotecan with temozolomide was safe and is reasonable palliative therapy. A formal Phase II study using a uniform dose and schedule is warranted to better define activity.
Related Papers
- → A Phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma(2006)44 cited
- → LTBK-04 FIRST RESULTS OF THE RANDOMIZED PHASE II STUDY ON DEPATUX –M ALONE, DEPATUX-M IN COMBINATION WITH TEMOZOLOMIDE AND EITHER TEMOZOLOMIDE OR LOMUSTINE IN RECURRENT EGFR AMPLIFIED GLIOBLASTOMA: FIRST REPORT FROM INTELLANCE 2/EORTC TRIAL 1410(2017)13 cited
- → Phase 2 study of BCNU and temozolomide for recurrent glioblastomamultiforme: North American Brain Tumor Consortium study(2004)67 cited
- → A Multicenter Phase I Trial of Interferon- and Temozolomide Combination Therapy for High-grade Gliomas (INTEGRA Study)(2008)18 cited
- → Chemotherapy for Kaposi Sarcoma(1976)1 cited